Top Markets
Coin of the day
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Peringkat dalam Saham #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Harga Saham
$1.00
Terakhir disinkronkan: 2023-06-01
Kapitalisasi Pasar
$30.11M
Perubahan (1 hari)
2.04%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Angion Biomedica Corp. (ANGN)

Kategori

Riwayat hasil dividen untuk Angion Biomedica Corp. (ANGN)
Hasil dividen (TTM) dari Angion Biomedica Corp. (simbol saham: ANGN) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Angion Biomedica Corp. (ANGN) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
Perusahaan Hasil Dividen Negara
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH